<DOC>
	<DOCNO>NCT02243553</DOCNO>
	<brief_summary>Primary : To quantify influence single-dose steady-state tipranavir/ritonavir 500/200 mg intestinal hepatic cytochrome P450 ( CYP ) P-glycoprotein ( P-gp ) biomarkers , mean predict drug interaction . The AUCs biomarkers caffeine , warfarin , omeprazole , dextromethorphan , midazolam , digoxin assess .</brief_summary>
	<brief_title>Effects Tipranavir ( With Ritonavir ) Capsule Liquid Formulation Cytochrome P450 P-glycoprotein Activity Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>1 . Signed informed consent 2 . Healthy subject age 18 year 45 year inclusive 3 . Weighing least 50 kg 4 . Volunteers must hospitalize Days 14 , 79 , 1720 pharmacokinetic assessment biomarker TPV/r ( Days 79 1720 ) 5 . Volunteers must willing complete studyrelated activity 6 . Each volunteer must valid social security number 7 . Each volunteer must acceptable medical history , physical examination laboratory test 1 . History presence allergy study drug component drug class , history drug allergy , opinion physician responsible , contraindicate participation 2 . Any finding medical examination ( include blood pressure , pulse rate electrocardiogram ) deviate normal clinical relevance 3 . History diagnosis significant medical condition : Including limit gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunologic , hematological , psychiatric , neurological , oncological hormonal disorder 4 . Known elevate liver enzyme past clinical trial compound ( experimental market ) 5 . Clinically relevant laboratory abnormality ( e.g . Hgb &lt; 11g/dL , Hct &lt; 30g/dL , total cholesterol &gt; 240mg/dL , triglyceride &gt; 500mg/dL , fast glucose &gt; 130mg/dL , liver function test &gt; 2.5x upper limit normal , baseline international normalize ratio &gt; 1.2 ) 6 . History evidence clinically significant hepatic , cardiac , pulmonary , endocrine , immunological , gastrointestinal , hematological , vascular collagen disease 7 . History alcohol abuse use illicit drug 8 . Unable abstain one beer alcohol equivalent per day duration study 9 . Use tobacco product and/or history smoking within past 2 month 10 . Pregnant breast feed 11 . Sexually active woman childbearing age use acceptable barrier method birth control 12 . Hypersensitivity caffeine , warfarin , vitamin K , omeprazole , dextromethorphan , midazolam , tipranavir , ritonavir excipients 13 . Concomitant treatment experimental compound 14 . Concomitant administration prescription counter medication know alter P450 enzyme Pgp activity 15 . Concomitant administration prescription counter medication know highly dependent P450 Pgp clearance elevate plasma concentration know associated serious toxicity 16 . Concomitant administration food product know alter P450 enzyme Pgp activity grapefruit juice , Seville oranges 17 . Concomitant administration drug could affect bleed ( e.g. , aspirin , clopidogrel , ticlopidine , warfarin , heparin , lowmolecular weight heparin ) 18 . Concomitant administration oral contraceptive ( may include 7day washout period ) 19 . Concomitant administration herbal medication 20 . Inadequate venous access 21 . Renal hepatic insufficiency 22 . Clinically unacceptable result screen physical examination 23 . Use investigational medication within 30 day study entry 24 . HIVpositive 25 . Body Mass Index ( BMI ) &gt; 30 kg/mÂ²</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>